Status:
COMPLETED
Ex-Vivo Reversion of Platelet Inhibition Induced by Prasugrel
Lead Sponsor:
University Hospital, Geneva
Conditions:
Acquired Platelet Disorder
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this ex-vivo study is to estimate the optimal platelet quantity necessary to reverse the antiplatelet effects of prasugrel.
Eligibility Criteria
Inclusion
- Acute coronary syndrome
- Prasugrel loading dose 6-24h before inclusion
Exclusion
- Clopidogrel loading dose
- GPIIbIIIa use within 10 days before inclusion
- Known congenital thrombopathy and/or congenital coagulation defect
Key Trial Info
Start Date :
September 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2014
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT01839968
Start Date
September 1 2011
End Date
January 1 2014
Last Update
August 19 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Geneva
Geneva, Canton of Geneva, Switzerland, 1205